The effect of istradefylline for Parkinson’s disease: A meta-analysis
暂无分享,去创建一个
[1] K. Hirata,et al. Istradefylline improves daytime sleepiness in patients with Parkinson's disease: An open-label, 3-month study , 2017, Journal of the Neurological Sciences.
[2] David Eidelberg,et al. Parkinson's disease‐related network topographies characterized with resting state functional MRI , 2017, Human brain mapping.
[3] Chris C. Tang,et al. Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases , 2016, Neurology.
[4] N. Shinohara,et al. Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson's disease , 2016, International journal of urology : official journal of the Japanese Urological Association.
[5] R. Kaji,et al. The difference of apparent diffusion coefficient in the middle cerebellar peduncle among parkinsonian syndromes: Evidence from a meta-analysis , 2016, Journal of the Neurological Sciences.
[6] Y. Mizuno,et al. A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease , 2015, Clinical neuropharmacology.
[7] T. J. Moore,et al. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. , 2014, JAMA internal medicine.
[8] R. Kaji,et al. Reduced alpha‐synuclein in cerebrospinal fluid in synucleinopathies: Evidence from a meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.
[9] H. Reichmann,et al. Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials , 2014, European journal of neurology.
[10] R. Kaji,et al. Which target is best for patients with Parkinson's disease? A meta-analysis of pallidal and subthalamic stimulation , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[11] Y. Mizuno,et al. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease , 2013, Movement disorders : official journal of the Movement Disorder Society.
[12] C. Tanner,et al. Caffeine consumption and risk of dyskinesia in CALM‐PD , 2013, Movement disorders : official journal of the Movement Disorder Society.
[13] Hongquan Wang,et al. Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: A meta-analysis , 2013, Journal of the Neurological Sciences.
[14] M. Schwarzschild,et al. Adenosine A2A receptor gene disruption protects in an α‐synuclein model of Parkinson's disease , 2012, Annals of neurology.
[15] M. Stacy,et al. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. , 2012, Parkinsonism & related disorders.
[16] C. Gerfen,et al. Modulation of striatal projection systems by dopamine. , 2011, Annual review of neuroscience.
[17] F. Turkheimer,et al. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease , 2011, Neurology.
[18] Y. Mizuno,et al. Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled study , 2010, Movement disorders : official journal of the Movement Disorder Society.
[19] Anatol C. Kreitzer,et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry , 2010, Nature.
[20] J. Jankovic,et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study , 2010, Annals of neurology.
[21] R. Hauser,et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations , 2008, Movement disorders : official journal of the Movement Disorder Society.
[22] M. Stacy,et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease , 2008, Neurology.
[23] P. Tuite,et al. Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005) , 2008, Annals of neurology.
[24] F. Schmidt. Meta-Analysis , 2008 .
[25] E. Oztaş,et al. Novel neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinson's disease , 2006, Journal of the Neurological Sciences.
[26] Miguel A Hernán,et al. A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.
[27] 賢二 鈴木. 慢性副鼻腔炎に対するrandomized controlled study , 2002 .
[28] K. Ikeda,et al. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease , 2002, Journal of neurochemistry.
[29] G. E. Alexander,et al. Functional architecture of basal ganglia circuits: neural substrates of parallel processing , 1990, Trends in Neurosciences.
[30] G. Liang,et al. Efficacy of Adenosine A2A Receptor Antagonist Istradefylline as Augmentation for Parkinson’s Disease: A Meta-analysis of Randomized Controlled Trials , 2014, Cell Biochemistry and Biophysics.
[31] R. Zweig,et al. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. , 2010, Parkinsonism & related disorders.
[32] Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. , 2009, Archives of neurology.